GSK

News

GSK enters PARP space with TESARO acquisition

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).

Partner Content

Partner Content

GSK and Sanofi to Present the Opening Keynote Sessions

Cold Chain Distribution Conference

News

Tafenoquine - single shot malaria cure endorsed by the FDA a...

The US Food and Drugs Administration Advisory Committee has endorsed tafenoquine, a single-dose drug from the GSK pipeline that targets one of the most frequent and widely distributed malar

News

GSK collaborates on AI-driven drug design with Cloud Pharmac...

GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals.

News

GSK strengthens core prescription business with Sin hire

In a drive to boost its search for innovative products worldwide, GlaxoSmithKline (GSK) has hired Kevin Sin from Roche.

News

GSK welcomes Brexit transition deal, but wants more 'precisi...

The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.

GSK enters PARP space with TESARO acquisition

GSK and Sanofi to Present the Opening Keynote Sessions

Tafenoquine - single shot malaria cure endorsed by the FDA a...

GSK collaborates on AI-driven drug design with Cloud Pharmac...

GSK strengthens core prescription business with Sin hire

GSK welcomes Brexit transition deal, but wants more 'precisi...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

GSK

Editor's Picks